BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-59@catalystbrief.girapphe.com
DTSTAMP:20261117T061552Z
LAST-MODIFIED:20261117T061552Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: MediciNova — MN-166 [Apr 2027]
DESCRIPTION:Phase 3 primary completion: Evaluation of MN-166 (Ibudilast) fo
 r 12 Months Followed by an Open-label Extension for 6 Months in Patients W
 ith ALS.\nSource: https://clinicaltrials.gov/study/NCT04057898\nhttps://ca
 talystbrief.girapphe.com/e/59?lang=en\nNot investment advice. Dates may ch
 ange.
URL:https://catalystbrief.girapphe.com/e/59?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
